Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WISARD: DTG/RPV Switch in HIV-1 with K103N
NCT05349838Phase 3Completed
- Sponsor
- NEAT ID Foundation
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of dolutegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by NEAT ID Foundation. Started Nov 2018; status: completed.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05349838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349838.